BAUSCH + LOMB CORP (BLCO) Stock Overview
USA - NYSE:BLCO - CA0717051076 - Common Stock
BLCO Key Statistics, Chart & Performance
The current stock price of BLCO is 15.09 USD. In the past month the price increased by 5.45%. In the past year, price decreased by -24.57%.
BLCO Latest News, Press Relases and Analysis
BLCO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.55 | 37.04B | ||
| COO | COOPER COS INC/THE | 17.45 | 13.94B | ||
| SOLV | SOLVENTUM CORP | 11.42 | 12.04B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.33 | 10.05B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.52 | 4.88B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.74 | 3.80B | ||
| ICUI | ICU MEDICAL INC | 15.92 | 2.96B | ||
| XRAY | DENTSPLY SIRONA INC | 7.41 | 2.53B | ||
| HAE | HAEMONETICS CORP/MASS | 10.73 | 2.40B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.48B | ||
| UFPT | UFP TECHNOLOGIES INC | 21.44 | 1.43B | ||
| NEOG | NEOGEN CORP | 20.02 | 1.30B |
Related stock screener links
About BLCO
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13500
Phone: 19082552864
BAUSCH + LOMB CORP / BLCO FAQ
What does BLCO do?
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
What is the current price of BLCO stock?
The current stock price of BLCO is 15.09 USD. The price decreased by -2.46% in the last trading session.
What is the dividend status of BAUSCH + LOMB CORP?
BLCO does not pay a dividend.
What is the ChartMill rating of BAUSCH + LOMB CORP stock?
BLCO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for BLCO stock?
The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 6.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of BLCO stock?
BAUSCH + LOMB CORP (BLCO) has a market capitalization of 5.34B USD. This makes BLCO a Mid Cap stock.
What is the next earnings date for BLCO stock?
BAUSCH + LOMB CORP (BLCO) will report earnings on 2026-02-13, before the market open.
BLCO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BLCO. When comparing the yearly performance of all stocks, BLCO is a bad performer in the overall market: 76.64% of all stocks are doing better.
BLCO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCO. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BLCO Financial Highlights
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.43. The EPS decreased by -29.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.97% | ||
| ROE | -4.24% | ||
| Debt/Equity | 0.77 |
BLCO Forecast & Estimates
20 analysts have analysed BLCO and the average price target is 15.43 USD. This implies a price increase of 2.24% is expected in the next year compared to the current price of 15.09.
For the next year, analysts expect an EPS growth of -12.99% and a revenue growth 6.68% for BLCO